l libraries using its proprietary, high-throughput cellular redistribution assay (CRA). Omeros has announced that it has identified and confirmed sets of compounds that interact selectively with 14 orphan receptors linked to esophageal squamous cell carcinoma and obesity-related type-2 diabetes (GPR39), squamous cell carcinoma (GPR87), pancreatic cancer (GPR182), acute lymphoblastic leukemia (P2Y8/P2RY8), sleep disorders (OPN4), cognitive disorders (GPR12), bipolar disorder and schizophrenia (GPR78), psychotic and metabolic disorders (GPR27, GPR85, GPR173), appetite control (GPR101), rheumatoid arthritis and HIV-mediated enteropathy (GPR15), motor control (GPR139) and congenital cataracts and birth defects of the brain and spinal cord (GPR161). The CRA detects receptor antagonists and agonists. Antagonists comprise the majority of marketed drugs, and all of the compounds characterized so far by Omeros are antagonists.
About G Protein-Coupled Receptors
GPCRs, which mediate key physiological processes in the body, are one of the most valuable families of drug targets. According to Insight Pharma Reports, GPCR-targeting drugs represent 30 to 40 percent of marketed pharmaceuticals. Examples include Claritin® (allergy), Zantac® (ulcers and reflux), OxyContin® (pain), Lopressor® (high blood pressure), Imitrex® (migraine headache), Reglan® (nausea) and Abilify® (schizophrenia, bipolar disease and depression) as well as all other antihistamines, opioids, alpha and beta blockers, serotonergics and dopaminergics.
The industry focuses its GPCR drug discovery efforts mostly on non-sensory GPCRs. Of the 363 total non-sensory GPCRs, approximately 240 have known ligands (molecules that bind the receptors) with nearly half of those targeted either by marketed drugs (46 GPCRs) or by drugs in development (about 70 GPCRs). There are approximately 120 GPCRs with no known ligands, which are termed "orphan GPCRs." WitPage: 1 2 3 4 Related medicine technology :1
. Omeros Unlocks Orphan GPCRs Linked to Leukemia and Sleep Disorders2
. Omeros Reports Allowance of Additional Patent for Arthroscopic Product3
. Omeros Announces Clinical Development Programs for OMS103HP and OMS3024
. Omeros Corporation Reports First Quarter 2011 Financial Results5
. Omeros Announces Expansion of Potential Indications for PDE7 Inhibitors6
. Omeros Announces Publication of MASP-2 Data in Proceedings of the National Academy of Sciences7
. Omeros Reports Outcome of Phase 3 Trials of OMS103HP8
. Omeros Corporation Reports Fourth Quarter and Year-End 2010 Financial Results9
. Omeros Unlocks Orphan GPCRs Linked to Pancreatic Cancer and Cognitive Disorders10
. Omeros Announces Expansion of Exclusive License to PDE7 Inhibitors from Daiichi Sankyo11
. Omeros Announces Publication of Data From Antifibrinolytic Program